Compounds > rubitecan
Page last updated: 2024-08-24

rubitecan and Local Neoplasm Recurrence

rubitecan has been researched along with Local Neoplasm Recurrence in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baron, B; Chollet, P; de Jonge, MJ; de Wit, R; Droz, JP; Fumoleau, P; Lacombe, D; Mettinger, K; Paz-Ares, L; van Oosterom, AT1
Caponigro, F; Cartenì, G; Davis, WB; Droz, JP; Milano, A; Pollard, P1
Herzog, TJ; Wethington, SL; Wright, JD1
Campone, M; Chollet, P; Fety-Deporte, R; Fumoleau, P; Lacombe, D; Lesimple, T; Menten, J; Paoletti, X; Raymond, E; Stupp, R1

Reviews

1 review(s) available for rubitecan and Local Neoplasm Recurrence

ArticleYear
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.
    Expert review of anticancer therapy, 2008, Volume: 8, Issue:5

    Topics: Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan

2008

Trials

3 trial(s) available for rubitecan and Local Neoplasm Recurrence

ArticleYear
Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors.
    Investigational new drugs, 2004, Volume: 22, Issue:3

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Topoisomerase I Inhibitors; Treatment Outcome; Urologic Neoplasms; Urothelium

2004
Phase II study of rubitecan in recurrent or metastatic head and neck cancer.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local

2008
Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:10

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Tomography, X-Ray Computed

2002